5-AZC
Showing 1 - 25 of >10,000
Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome Trial in Columbus (Azacitidine, Quality-of-Life
Recruiting
- Secondary Myelodysplastic Syndrome
- Therapy-Related Myelodysplastic Syndrome
- Azacitidine
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Dec 1, 2022
Acute Myeloid Leukemia Trial in Los Angeles, San Francisco (Azacitidine, Tagraxofusp-erzs)
Not yet recruiting
- Acute Myeloid Leukemia
- Azacitidine
- Tagraxofusp-erzs
-
Los Angeles, California
- +1 more
Jan 31, 2023
Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation, Hematologic and Lymphocytic Disorder Trial in Houston (Azacitidine,
Recruiting
- Acute Myeloid Leukemia in Remission
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Dec 13, 2022
High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome Trial in Houston (Azacitidine,
Active, not recruiting
- High Risk Myelodysplastic Syndrome
- +2 more
- Azacitidine
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Aug 11, 2022
Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2 Trial in Houston
Active, not recruiting
- Chronic Myelomonocytic Leukemia-0
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Jan 18, 2023
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome Trial in Scottsdale, Cleveland,
Completed
- Chronic Myelomonocytic Leukemia
- +3 more
- Azacitidine
- +2 more
-
Scottsdale, Arizona
- +3 more
Jan 12, 2023
Acute Myeloid Leukemia Trial in Chicago (Azacitidine, Biospecimen Collection, Bone Marrow Aspirate)
Not yet recruiting
- Acute Myeloid Leukemia
- Azacitidine
- +5 more
-
Chicago, IllinoisNorthwestern University
Feb 16, 2023
Acute Myeloid Leukemia Trial in Sacramento (Azacitidine, Uproleselan, Venetoclax)
Recruiting
- Acute Myeloid Leukemia
- Azacitidine
- +2 more
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Aug 12, 2022
Myelodysplastic/Myeloproliferative Tumor, Unclassifiable, Myelofibrosis Transformation in Essential Thrombocythemia,
Recruiting
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
- +3 more
- Azacitidine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Duarte (procedure, drug, biological, other)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Allogeneic Hematopoietic Stem Cell Transplantation
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
Apr 10, 2023
Chronic Myelomonocytic Leukemia Trial in Houston (Azacitidine, Tamibarotene, Venetoclax)
Not yet recruiting
- Chronic Myelomonocytic Leukemia
- Azacitidine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 10, 2023
Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Recruiting
- Acute Bilineal Leukemia
- +8 more
- Azacitidine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jan 24, 2023
Acute Myeloid Leukemia Trial in Houston (Azacitidine, Venetoclax, NK Cells)
Not yet recruiting
- Acute Myeloid Leukemia
- Azacitidine
- +2 more
-
Houston, TexasM.D. Anderson Cancer Center
Apr 17, 2023
Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia Trial
Recruiting
- Recurrent Chronic Myelomonocytic Leukemia
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Jul 21, 2022
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Anti-OX40 Agonist Monoclonal Antibody
Active, not recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Anti-OX40 Agonist Monoclonal Antibody PF-04518600
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Jan 25, 2022
Acute Myeloid Leukemia Trial in Columbus (Azacitidine, Biopsy, Enasidenib)
Not yet recruiting
- Acute Myeloid Leukemia
- Azacitidine
- +4 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Jun 30, 2022
Hodgkin's Lymphoma Trial in Houston (Azacytidine, Pembrolizumab)
Recruiting
- Hodgkin's Lymphoma
-
Houston, TexasMD Anderson Cancer Center
Oct 5, 2022
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Tumor Trial in Houston (Azacitidine, Quizartinib)
Recruiting
- Chronic Myelomonocytic Leukemia
- +5 more
-
Houston, TexasM D Anderson Cancer Center
May 23, 2022
Leukemia Trial in Houston (Brentuximab Vedotin, 5-Azacytidine)
Terminated
- Leukemia
- Brentuximab Vedotin
- 5-Azacytidine
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 7, 2022
Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia Trial in Columbus (Azacitidine,
Recruiting
- Acute Myeloid Leukemia
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Jan 4, 2022
Acute Myeloid Leukemia Trial in Houston (Azacitidine, Cladribine, Cytarabine)
Recruiting
- Acute Myeloid Leukemia
- Azacitidine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Nov 17, 2022
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells Trial in
Recruiting
- Acute Myeloid Leukemia
- +7 more
- Azacitidine
- +3 more
-
New Brunswick, New JerseyRutgers Cancer Institute of New Jersey
May 16, 2022
Melanoma and Other Malignant Tumors of Skin, Metastatic Melanoma Trial in Houston (Azacitidine, Pembrolizumab)
Active, not recruiting
- Melanoma and Other Malignant Neoplasms of Skin
- Metastatic Melanoma
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Oct 31, 2022
Acute Myeloid Leukemia With Multilineage Dysplasia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Blasts 20-30 Percent of
Active, not recruiting
- Acute Myeloid Leukemia With Multilineage Dysplasia
- +6 more
- Azacitidine
- Glutaminase Inhibitor CB-839
-
Houston, TexasM D Anderson Cancer Center
Feb 25, 2022
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia Trial in Los Angeles, Sacramento, Oklahoma City (Azacitidine,
Recruiting
- Acute Myeloid Leukemia
- Recurrent Acute Myeloid Leukemia
- Azacitidine
- +2 more
-
Los Angeles, California
- +2 more
Mar 11, 2022